The FDA approval of ORLYNVAH TM is a significant milestone for Iterum Therapeutics, likely boosting investor confidence and stock price. The extended cash runway and focus on strategic partnerships and pre-commercialization efforts indicate a positive outlook for the company's future, particularly in addressing the unmet need for uUTI treatments.